Zacks Research Downgrades Phibro Animal Health (NASDAQ:PAHC) to Hold

Phibro Animal Health (NASDAQ:PAHC) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

PAHC has been the topic of several other research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. JPMorgan Chase & Co. raised their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a report on Friday. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Phibro Animal Health has an average rating of “Hold” and a consensus price target of $37.50.

Phibro Animal Health Stock Up 0.4%

Shares of PAHC traded up $0.20 during trading hours on Monday, hitting $51.94. The stock had a trading volume of 123,056 shares, compared to its average volume of 257,229. Phibro Animal Health has a 1-year low of $16.16 and a 1-year high of $56.30. The firm has a market capitalization of $2.10 billion, a P/E ratio of 23.08, a price-to-earnings-growth ratio of 0.80 and a beta of 0.80. The firm has a 50 day simple moving average of $40.54 and a 200-day simple moving average of $38.75. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The business had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Sell-side analysts predict that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 110,842 shares of the business’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $48.38, for a total value of $5,362,535.96. Following the transaction, the chief executive officer directly owned 122,958 shares in the company, valued at $5,948,708.04. The trade was a 47.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 221,723 shares of company stock worth $9,994,145 in the last three months. Company insiders own 50.13% of the company’s stock.

Institutional Trading of Phibro Animal Health

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Phibro Animal Health by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock valued at $57,519,000 after buying an additional 13,884 shares during the last quarter. Geode Capital Management LLC raised its stake in Phibro Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock valued at $21,265,000 after acquiring an additional 21,951 shares during the period. Millennium Management LLC lifted its holdings in Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after purchasing an additional 154,281 shares during the last quarter. Ranger Investment Management L.P. boosted its position in Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after purchasing an additional 179,975 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Phibro Animal Health by 22.5% in the third quarter. Invesco Ltd. now owns 322,299 shares of the company’s stock worth $13,040,000 after purchasing an additional 59,226 shares in the last quarter. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.